Abstract
Disruption of the mouse dopamine transporter gene results in spontaneous hyperlocomotion despite major adaptive changes, such as decreases in neurotransmitter and receptor levels. In homozygote mice, dopamine persists at least 100 times longer in the extracellular space, explaining the biochemical basis of the hyperdopaminergic phenotype and demonstrating the critical role of the transporter in regulating neurotransmission. The dopamine transporter is an obligatory target of cocaine and amphetamine, as these psychostimulants have no effect on locomotor activity or dopamine release and uptake in mice lacking the transporter.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Iversen, L. L. Br. J. Pharmac. 41, 571–591 (1971).
Amara, S. G. & Kuhar, M. J. A. Rev. Neurosci. 16, 16–73 (1993).
Giros, B. & Caron, M. G. Trends pharmac. Sci. 14, 43–49 (1993).
Ritz, M. C., Lamb, R. J., Goldberg, S. R. & Kuhar, M. J. Science 237, 1219–1223 (1987).
Horn, A. S. Prog. Neurobiol. 34, 387–400 (1990).
Pifl, C., Giros, B. & Caron, M. G. J. Neurosci. 13, 4246–4253 (1993).
Kitayama, S. et al. Proc. natn. Acad. Sci. U.S.A. 89, 7782–7785 (1992).
Giros, B. et al. J. biol. Chem. 269, 15985–15988 (1994).
Buck, K. J. & Amara, S. G. Proc. natn. Acad. Sci. U.S.A. 91, 12584–12588 (1994).
Barker, E. L., Kimmel, H. L. & Blakely, R. D. Molec. Pharmac. 46, 799–807 (1994).
Giros, B., El Mestikawy, S., Bertrand, L. & Caron, M. G. FEBS Lett. 295, 149–154 (1991).
Cerruti, C., Walther, D. M., Kuhar, M. J. & Uhl, G. R. Molec. Brain Res. 18, 181–186 (1993).
Ciliax, B. J. et al. J. Neurosci. 15, 1714–1723 (1995).
Zhou, Q.-Y., Quaife, C. J. & Palmiter, R. D. Nature 374, 640–643 (1995).
Drago, J. et al. Proc. natn. Acad. Sci. U.S.A. 91, 12564–12568 (1994).
Xu, M. et al. Cell 79, 729–742 (1994).
Balk, J.-H. et al. Nature 377, 424–428 (1995).
Fuller, R. W., Wong, D. T. & Robertson, D. W. Med. Res. Rev. 11, 17–34 (1991).
Wise, R. A. & Bozarth, M. A. Psychiat. Med. 3, 445–460 (1985).
Fisher, J. F. & Cho, A. K. J. Pharmac. exp. Ther. 208, 203–209 (1979).
Hitri, A., Hurd, Y. L., Wyatt, R. J. & Deutsch, S. I. Clin. Neuropharmac. 17, 1–22 (1994).
Eshelman, A. Y., Henningsen, R. A., Neve, K. A. & Janowsky, A. J. Molec. Pharmac. 45, 312–316 (1994).
Sulzer, D. et al. J. Neurosci. 15, 4102–4108 (1995).
Kohler, B. H. & Smithies, O. Proc. natn. Acad. Sci. U.S.A. 86, 8932–8935 (1989).
Byck, R. & VanDyke, C. NIDA Monogr. 13, 97–118 (1977).
Meister, B. & Elde, R. Neuroendocrinology 58, 388–395 (1993).
Baumann, M. H. & Rothman, R. B. Brain Res. 608, 175–179 (1993).
Zimmerberg, B. & Gray, M. S. Physiol. Behav. 52, 379–384 (1992).
Kelly, P. H., Seviour, P. W. & Iversen, S. D. Brain Res. 94, 507–522 (1975).
Di Chiara, G. & Imperato, A. Proc. natn. Acad. Sci. U.S.A. 85, 5274–5278 (1988).
Jaber, M. et al. Neuroscience 65, 1041–1050 (1995).
Gerfen, C. R. Trends Neurosci. 15, 133–138 (1992).
Le Moine, C. et al. Proc. natn. Acad. Sci. U.S.A. 87, 230–234 (1990).
Le Moine, C., Normand, E. & Bloch, B. Proc. natn. Acad. Sci. U.S.A. 88, 4205–4209 (1991).
Chiodo, L. A. Neurochem. Int. 26, 815–845 (1992).
Kawagoe, K. T., Zimmerman, J. B. & Wightman, R. M. J. Neurosci. Meth. 48, 225–240 (1993).
Wightman, R. M. & Zimmerman, J. B. Brain Res. Rev. 15, 135–144 (1990).
Jones, S. R., Garris, P. A., Kilts, C. D. & Wightman, R. M. J. Neurochem. 64, 2581–2589 (1995).
Raiteri, M., Cerrito, F., Cervoni, A. M. & Levi, G. J. Pharmac. exp. Ther. 208, 195–202 (1979).
Wall, S. C., Gu, H. & Rudnick, G. Molec. Pharmac. 47, 544–550 (1995).
Parker, E. M. & Cubeddu, L. X. J. Pharmac. exp. Ther. 237, 179–192 (1986).
Jacocks, H. M. & Cox, B. M. J. Pharmac. exp. Ther. 262, 356–364 (1992).
Crow, T. J. Br. J. Psychiat. 137, 383–386 (1980).
Ehringer, H. & Hornykiewicz, O. Klin. Wschr. 38, 1236–1239 (1960).
Koob, G. F. & Bloom, F. E. Science 242, 715–723 (1988).
Graham, J. H., Maher, J. R. & Robinson, S. E. J. Pharmac. exp. Ther. 174, 707–717 (1995).
Tison, F., Normand, E. & Bloch, B. Neurosci. Lett. 166, 48–50 (1994).
Kennedy, R. T., Jones, S. R. & Wightman, R. M. J. Neurochem. 59, 449–455 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Giros, B., Jaber, M., Jones, S. et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606–612 (1996). https://doi.org/10.1038/379606a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/379606a0
This article is cited by
-
The molecular pathology of schizophrenia: an overview of existing knowledge and new directions for future research
Molecular Psychiatry (2023)
-
Cocaine induces locomotor sensitization through a dopamine-dependent VTA-mPFC-FrA cortico-cortical pathway in male mice
Nature Communications (2023)
-
Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine physiology in VPS35 p.D620N knock-in mice
npj Parkinson's Disease (2023)
-
Dopaminergic and cholinergic modulation of the amygdala is altered in female mice with oestrogen receptor β deprivation
Scientific Reports (2023)
-
Distinct sub-second dopamine signaling in dorsolateral striatum measured by a genetically-encoded fluorescent sensor
Nature Communications (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.